TP53 and neoplasm: The novel MDM2 inhibitor APG-115 is believed to possess a higher affinity for MDM2 than other MDM2-p53 inhibitors, which can result in the inhibition of tumor cell proliferation and an enhancement in radiotherapy sensitivity.